Consistent Pharmacokinetic Profile
One IU of AlphaNine SD infused per kg of body weight raises the recipient's plasma factor IX level by 1%.
Summary of the pharmacokinetic parameters of AlphaNine SD1
|Parameter||PK1 Mean (±SD) (n = 25)||PK2 Mean (±SD) (n = 23)|
|Recovery (IU dL-1 per IU kg-1||1.01 ± 0.19||1.23 ± 0.34|
|Terminal half-life (t1/2) (h)*||34.5 ± 6.2||33.7 ± 5.4|
|Area under the curve (AUC0-74h) (IU x h dL-1)||1351.8 ± 260.7||1442.0 ± 246.1|
|Area under the curve (AUC0-∞) (IU x h dL-1)||1601.6 ± 312.1||1643.7 ± 360.0|
|Clearance (CL) (dL min-1)||0.076 ± 0.02||0.071 ± 0.01|
|Mean residence time (MRT) (h)||35.76 ± 5.4||34.63 ± 5.2|
|Parameter||Recovery (IU dL-1 per IU kg-1|
|PK1 Mean (±SD) (n = 25)||1.01 ± 0.19|
|PK2 Mean (±SD) (n = 23)||1.23 ± 0.34|
|Parameter||Terminal half-life (t1/2) (h)*|
|PK1 Mean (±SD) (n = 25)||34.5 ± 6.2|
|PK2 Mean (±SD) (n = 23)||33.7 ± 5.4|
|Parameter||Area under the curve (AUC0-74h) (IU x h dL-1)|
|PK1 Mean (±SD) (n = 25)||1351.8 ± 260.7|
|PK2 Mean (±SD) (n = 23)||1442.0 ± 246.1|
|Parameter||Area under the curve (AUC0-∞) (IU x h dL-1)|
|PK1 Mean (±SD) (n = 25)||1601.6 ± 312.1|
|PK2 Mean (±SD) (n = 23)||1643.7 ± 360.0|
|Parameter||Clearance (CL) (dL min-1)|
|PK1 Mean (±SD) (n = 25)||0.076 ± 0.02|
|PK2 Mean (±SD) (n = 23)||0.071 ± 0.01|
|Parameter||Mean residence time (MRT) (h)|
|PK1 Mean (±SD) (n = 25)||35.76 ± 5.4|
|PK2 Mean (±SD) (n = 23)||34.63 ± 5.2|
Results from a pharmacokinetic, efficacy and safety study in 25 severe hemophilia B patients treated with AlphaNine SD, which compared the first AlphaNine SD pharmacokinetics with a second assessment after 6 months of treatment.1
AlphaNine SD was infused at a single dose of 65-76 IU/kg and FIX activity was determined at pre-infusion and different times until 74 hours post-infusion.1
AlphaNine® SD (coagulation factor IX [human]) is indicated for the prevention and control of bleeding in patients with Factor IX deficiency due to hemophilia B.
AlphaNine SD is made from human plasma. Plasma products carry a risk of transmitting infectious agents, including viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk.
Incidences of thrombosis or disseminated intravascular coagulation (DIC) have been reported following administration of Factor IX Complex concentrates which contain high amounts of Factor II, VII, and X. AlphaNine SD contains low, nontherapeutic levels of Factor II, VII, and X.
Following administration in surgery patients and individuals with known liver disease, the physician should closely observe the patient for signs and symptoms of potential disseminated intravascular coagulation.
Allergic type hypersensitivity reactions, including anaphylaxis, have been reported for all factor IX products. The administration of plasma preparations may cause allergic reactions, mild chills, nausea or stinging at the infusion site.
Nephrotic syndrome has been reported following attempted immune tolerance induction with factor IX products in hemophilia B patients with factor IX inhibitors and a history of severe allergic reactions to Factor IX.
In order to minimize the possibility of thrombogenic complications, dosing guidelines should be strictly followed.
AlphaNine SD should not be administered at a rate exceeding 10 mL/ minute. Rapid administration may result in vasomotor reactions.
Please see full Prescribing Information for AlphaNine SD.
- Lissitchkov T, Matysiak M, Zavilska K, et al. A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B. Haemophilia. 2011;17(4):590-596.